The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function

G. Everson, K. C. Lasseter, Karl Anderson, L. A. Bauer, R. L. Carithens, K. D. Wilner, A. Johnson, R. J. Anziano, T. A. Smolarek, R. Z. Turncliff

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Aims. To assess whether hepatic impairment influences the pharmacokinetics of ziprasidone. Methods. Thirty subjects with normal hepatic function or a primary diagnosis of clinically significant cirrhosis (Child-Pugh A or B) were enrolled into an open-label, multicentre, multiple-dose study. The subjects with chronic, stable hepatic impairment and the matched control subjects received ziprasidone 40 mg day-1, given orally with food, as two divided daily doses for 4 days and a single 20 mg dose on the morning of day 5. Pharmacokinetic variables were determined from multiple venous blood samples collected on days 1 and 5. Liver function was evaluated quantitatively using antipyrine. Results. On day 1 there were no statistically significant differences in the pharmacokinetics (AUC(0,12 h), C(max), t(max)) of ziprasidone between the two groups. On day 5 there were no statistically significant differences in the C(max) or t(max) for ziprasidone between the two groups. The mean AUC(0,12 h) for ziprasidone was statistically significantly greater in the hepatically impaired subjects compared with the normal subjects (590 ng ml-1 h vs 467 ng ml-1 h, P = 0.042). However, the AUC(0,12 h) increased by only 26% in the cirrhotic group compared with the matched control group. The ziprasidone λ(z) in the subjects with normal hepatic function was statistically significantly greater than that in the hepatically impaired subjects (P < 0.001). There was no correlation between antipyrine λ(z) and ziprasidone λ(z) in the subjects with normal hepatic function or in those with hepatic impairment. Conclusions. The findings of this study indicate that mild to moderate hepatic impairment does not result in clinically significant alteration of ziprasidone pharmacokinetics.

Original languageEnglish (US)
JournalBritish Journal of Clinical Pharmacology
Volume49
Issue numberSUPPL. 1
StatePublished - 2000

Fingerprint

Pharmacokinetics
Liver
Area Under Curve
Antipyrine
ziprasidone
Fibrosis
Research Design
Food
Control Groups

Keywords

  • Hepatic impairment
  • Metabolism
  • Pharmacokinetics
  • Ziprasidone

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology

Cite this

Everson, G., Lasseter, K. C., Anderson, K., Bauer, L. A., Carithens, R. L., Wilner, K. D., ... Turncliff, R. Z. (2000). The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. British Journal of Clinical Pharmacology, 49(SUPPL. 1).

The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. / Everson, G.; Lasseter, K. C.; Anderson, Karl; Bauer, L. A.; Carithens, R. L.; Wilner, K. D.; Johnson, A.; Anziano, R. J.; Smolarek, T. A.; Turncliff, R. Z.

In: British Journal of Clinical Pharmacology, Vol. 49, No. SUPPL. 1, 2000.

Research output: Contribution to journalArticle

Everson, G, Lasseter, KC, Anderson, K, Bauer, LA, Carithens, RL, Wilner, KD, Johnson, A, Anziano, RJ, Smolarek, TA & Turncliff, RZ 2000, 'The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function', British Journal of Clinical Pharmacology, vol. 49, no. SUPPL. 1.
Everson, G. ; Lasseter, K. C. ; Anderson, Karl ; Bauer, L. A. ; Carithens, R. L. ; Wilner, K. D. ; Johnson, A. ; Anziano, R. J. ; Smolarek, T. A. ; Turncliff, R. Z. / The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. In: British Journal of Clinical Pharmacology. 2000 ; Vol. 49, No. SUPPL. 1.
@article{e9ed7020aa5840bfac18bfeacb9d02ce,
title = "The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function",
abstract = "Aims. To assess whether hepatic impairment influences the pharmacokinetics of ziprasidone. Methods. Thirty subjects with normal hepatic function or a primary diagnosis of clinically significant cirrhosis (Child-Pugh A or B) were enrolled into an open-label, multicentre, multiple-dose study. The subjects with chronic, stable hepatic impairment and the matched control subjects received ziprasidone 40 mg day-1, given orally with food, as two divided daily doses for 4 days and a single 20 mg dose on the morning of day 5. Pharmacokinetic variables were determined from multiple venous blood samples collected on days 1 and 5. Liver function was evaluated quantitatively using antipyrine. Results. On day 1 there were no statistically significant differences in the pharmacokinetics (AUC(0,12 h), C(max), t(max)) of ziprasidone between the two groups. On day 5 there were no statistically significant differences in the C(max) or t(max) for ziprasidone between the two groups. The mean AUC(0,12 h) for ziprasidone was statistically significantly greater in the hepatically impaired subjects compared with the normal subjects (590 ng ml-1 h vs 467 ng ml-1 h, P = 0.042). However, the AUC(0,12 h) increased by only 26{\%} in the cirrhotic group compared with the matched control group. The ziprasidone λ(z) in the subjects with normal hepatic function was statistically significantly greater than that in the hepatically impaired subjects (P < 0.001). There was no correlation between antipyrine λ(z) and ziprasidone λ(z) in the subjects with normal hepatic function or in those with hepatic impairment. Conclusions. The findings of this study indicate that mild to moderate hepatic impairment does not result in clinically significant alteration of ziprasidone pharmacokinetics.",
keywords = "Hepatic impairment, Metabolism, Pharmacokinetics, Ziprasidone",
author = "G. Everson and Lasseter, {K. C.} and Karl Anderson and Bauer, {L. A.} and Carithens, {R. L.} and Wilner, {K. D.} and A. Johnson and Anziano, {R. J.} and Smolarek, {T. A.} and Turncliff, {R. Z.}",
year = "2000",
language = "English (US)",
volume = "49",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function

AU - Everson, G.

AU - Lasseter, K. C.

AU - Anderson, Karl

AU - Bauer, L. A.

AU - Carithens, R. L.

AU - Wilner, K. D.

AU - Johnson, A.

AU - Anziano, R. J.

AU - Smolarek, T. A.

AU - Turncliff, R. Z.

PY - 2000

Y1 - 2000

N2 - Aims. To assess whether hepatic impairment influences the pharmacokinetics of ziprasidone. Methods. Thirty subjects with normal hepatic function or a primary diagnosis of clinically significant cirrhosis (Child-Pugh A or B) were enrolled into an open-label, multicentre, multiple-dose study. The subjects with chronic, stable hepatic impairment and the matched control subjects received ziprasidone 40 mg day-1, given orally with food, as two divided daily doses for 4 days and a single 20 mg dose on the morning of day 5. Pharmacokinetic variables were determined from multiple venous blood samples collected on days 1 and 5. Liver function was evaluated quantitatively using antipyrine. Results. On day 1 there were no statistically significant differences in the pharmacokinetics (AUC(0,12 h), C(max), t(max)) of ziprasidone between the two groups. On day 5 there were no statistically significant differences in the C(max) or t(max) for ziprasidone between the two groups. The mean AUC(0,12 h) for ziprasidone was statistically significantly greater in the hepatically impaired subjects compared with the normal subjects (590 ng ml-1 h vs 467 ng ml-1 h, P = 0.042). However, the AUC(0,12 h) increased by only 26% in the cirrhotic group compared with the matched control group. The ziprasidone λ(z) in the subjects with normal hepatic function was statistically significantly greater than that in the hepatically impaired subjects (P < 0.001). There was no correlation between antipyrine λ(z) and ziprasidone λ(z) in the subjects with normal hepatic function or in those with hepatic impairment. Conclusions. The findings of this study indicate that mild to moderate hepatic impairment does not result in clinically significant alteration of ziprasidone pharmacokinetics.

AB - Aims. To assess whether hepatic impairment influences the pharmacokinetics of ziprasidone. Methods. Thirty subjects with normal hepatic function or a primary diagnosis of clinically significant cirrhosis (Child-Pugh A or B) were enrolled into an open-label, multicentre, multiple-dose study. The subjects with chronic, stable hepatic impairment and the matched control subjects received ziprasidone 40 mg day-1, given orally with food, as two divided daily doses for 4 days and a single 20 mg dose on the morning of day 5. Pharmacokinetic variables were determined from multiple venous blood samples collected on days 1 and 5. Liver function was evaluated quantitatively using antipyrine. Results. On day 1 there were no statistically significant differences in the pharmacokinetics (AUC(0,12 h), C(max), t(max)) of ziprasidone between the two groups. On day 5 there were no statistically significant differences in the C(max) or t(max) for ziprasidone between the two groups. The mean AUC(0,12 h) for ziprasidone was statistically significantly greater in the hepatically impaired subjects compared with the normal subjects (590 ng ml-1 h vs 467 ng ml-1 h, P = 0.042). However, the AUC(0,12 h) increased by only 26% in the cirrhotic group compared with the matched control group. The ziprasidone λ(z) in the subjects with normal hepatic function was statistically significantly greater than that in the hepatically impaired subjects (P < 0.001). There was no correlation between antipyrine λ(z) and ziprasidone λ(z) in the subjects with normal hepatic function or in those with hepatic impairment. Conclusions. The findings of this study indicate that mild to moderate hepatic impairment does not result in clinically significant alteration of ziprasidone pharmacokinetics.

KW - Hepatic impairment

KW - Metabolism

KW - Pharmacokinetics

KW - Ziprasidone

UR - http://www.scopus.com/inward/record.url?scp=0034061638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034061638&partnerID=8YFLogxK

M3 - Article

C2 - 10771450

AN - SCOPUS:0034061638

VL - 49

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - SUPPL. 1

ER -